



September 11, 2026

PeptiDream Inc.
<https://www.peptidream.com/en/>
(TSE Prime Market: 4587)

PeptiDream Publishes "Sustainability Impact Report 2026"

KANAGAWA, JAPAN – September 11, 2026 – PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (Representative Director & CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today published the "Sustainability Impact Report 2026" (Japanese and English versions) on its official website.



This year's report aims to enhance stakeholders' understanding of our sustainability initiatives by communicating our sustainability policies and recent activities. The 2026 edition highlights a wide range of activities across the three pillars of ESG: Environmental, Social, and Governance, including the strengthening of corporate governance through the introduction of a new leadership structure and the establishment of a Group-wide water consumption reduction target for 2030.

In 2026, PeptiDream proudly celebrates its 20th anniversary. Since our founding in 2006, we have pursued our mission of discovering the next generation of transformational medicines that will drastically improve the lives of patients worldwide. As we continue working toward this mission, we remain committed to advancing our sustainability initiatives while enhancing information disclosure and strengthening communication with our stakeholders.

The " Sustainability Impact Report 2026" is available at the following link:

https://www.peptidream.com/en/docs/ESG_report_2026_en.pdf

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en/

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Corporate Communications

Email: info@peptidream.com

Website: <https://www.peptidream.com/en/>

X: <https://x.com/PeptidreamInc>

LinkedIn: <https://www.linkedin.com/company/peptidream>